RESUMO
3H labelled thymidine, uridine and leucine were used to evaluate the synthesis of DNA, RNA and proteins in malignant cells and normal cells incubated with Ukrain in different concentrations. Compared with the controls, the inhibiting effects of Ukrain are demonstrated in guinea pig hepatocytes, CIL hepatocytes, human tonsil cells, two murine lymphomas, murine myeloma, Yoshida cells, two HeLa strains, EsB- and EB- (murine) lymphomas. YAC-1, P815 and human WiDr cells. Ukrain inhibits the DNA, RNA and protein synthesis in malignant cell lines at relatively high concentrations and to a small extent in normal cells.
Assuntos
Alcaloides/farmacologia , Antineoplásicos/farmacologia , DNA de Neoplasias/biossíntese , Proteínas de Neoplasias/biossíntese , Neoplasias Experimentais/tratamento farmacológico , Neoplasias Experimentais/metabolismo , RNA Neoplásico/biossíntese , Animais , Alcaloides de Berberina , Cobaias , Células HeLa , Humanos , Fígado/efeitos dos fármacos , Fígado/metabolismo , Linfoma/tratamento farmacológico , Linfoma/metabolismo , Camundongos , Mieloma Múltiplo/tratamento farmacológico , Mieloma Múltiplo/metabolismo , Tonsila Palatina/efeitos dos fármacos , Tonsila Palatina/metabolismo , Fenantridinas , Sarcoma de Yoshida/tratamento farmacológico , Sarcoma de Yoshida/metabolismoRESUMO
Tumour cells were taken from human tumour xenografts (HTX) and serially transplanted into nude mice. These cells were used in a colony-forming assay in vitro. Tumour cells were incubated continuously for at least one week with several concentrations of the drug Ukrain. This was done with six different types and the colony formation was scored for each tumour. The drug effects were reported as percent T/C (Test/Control) for the numbers of colonies formed. Activity is considered to be present at T/C < 30%. A clear dose-response effect was found for Ukrain.
Assuntos
Alcaloides/farmacologia , Antineoplásicos/farmacologia , Neoplasias/tratamento farmacológico , Animais , Alcaloides de Berberina , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Camundongos , Camundongos Nus , Transplante de Neoplasias , Neoplasias/patologia , Fenantridinas , Transplante HeterólogoRESUMO
Immunological changes are often seen in subjects suffering from oncological disease. Decreased NK activity, alterations of the T4/T8 quotient, decreased phagocytic activity, low reactivity and decreased recognition of the "foreign" are common features seen in these patients. Cytostatic therapy (chemotherapy and radiation therapy) very often enhance these negative properties, thus limiting therapeutic possibilities by highly toxic sequels. Ukrain, being cytostatic and immune-stimulating and modulating, has no adverse effects on the organism.
Assuntos
Alcaloides/farmacologia , Antineoplásicos/farmacologia , Granulócitos/efeitos dos fármacos , Granulócitos/imunologia , Reticulócitos/efeitos dos fármacos , Reticulócitos/imunologia , Linfócitos T/efeitos dos fármacos , Linfócitos T/imunologia , Animais , Alcaloides de Berberina , Sinergismo Farmacológico , Feminino , Células Matadoras Naturais/efeitos dos fármacos , Células Matadoras Naturais/imunologia , Ativação Linfocitária , Masculino , Fenantridinas , Fito-Hemaglutininas/farmacologia , Ratos , Ratos Wistar , Contagem de Reticulócitos/efeitos dos fármacos , Reticulócitos/citologia , Tiotepa/uso terapêuticoRESUMO
A patient with a metastasizing malignant melanoma (stage III) was treated with Ukrain monotherapy. Before and during the first Ukrain course of treatment the patient excreted melanin in the urine. After the third course melanin was no more detectable and the patient has been without any symptoms of disease for the last 12 years.
Assuntos
Alcaloides/uso terapêutico , Antineoplásicos/uso terapêutico , Melanoma/tratamento farmacológico , Adulto , Alcaloides de Berberina , Humanos , Metástase Linfática , Masculino , Melanoma/secundário , Estadiamento de Neoplasias , FenantridinasRESUMO
In a patient with low grade differentiated urethral carcinoma (histologically: urothelial carcinoma G2 and G3, pT1 with low grade differentiation) operation was carried out, with recurrence after two months. Instead of reoperation the patient was given Ukrain as monotherapy. No carcinoma was detected four months later by histological examination or during examinations three years later.
Assuntos
Alcaloides/uso terapêutico , Antineoplásicos/uso terapêutico , Recidiva Local de Neoplasia/tratamento farmacológico , Neoplasias Uretrais/tratamento farmacológico , Alcaloides de Berberina , Terapia Combinada , Humanos , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/cirurgia , Fenantridinas , Neoplasias Uretrais/cirurgiaRESUMO
This paper summarizes the preliminary results of two independent clinical trials conducted with the preparation "Ukrain", containing thiophosphoric acid alkaloid derivatives from the plant Chelidonium majus L. (greater celandine), in order to investigate whether it has immunopotentiating properties in cancer patients. A total of twenty-seven patients with various malignancies were treated with "Ukrain" given intravenously in a dose of 10 mg every three days. In all patients the cellular and humoral immune response was studied. There was an increase in both total T-cells and T-helper lymphocytes, a decrease in T-suppressor cells, and normalization of the helper/suppressor (HIS) ratio. A significant increase in erythrocyte-rosette-forming T-cells and NK cells was also demonstrated. Serum immunoglobulin levels, complement components (C3 and C4), and acute phase proteins were not significantly enhanced. Restoration of cellular immunity was accompanied by an improvement in the patients' performance status and in the clinical course of the disease. The treatment was generally well tolerated. The present study shows that some therapeutic benefit from the use of Chelidonium majus ("Ukrain") as an immunostimulant in cancer patients can be achieved.
